IRoc-GN国际登记:COVID-19合并肾小球疾病患者需密切监测
IRoc-GN国际登记纳入北美和欧洲40例合并COVID-19的肾小球肾炎患者,与80例无肾小球肾炎的COVID阳性对照按感染时间匹配。肾小球肾炎组死亡率(15% vs 5%)和急性肾损伤发生率(39% vs 14%)显著高于对照,肾脏替代治疗需求无统计学差异。就诊时低血清白蛋白和较短肾小球疾病病程与急性肾损伤及肾脏替代治疗风险相关。
要点
- 肾小球肾炎合并COVID-19患者死亡率15%、急性肾损伤39%,均高于无肾小球肾炎对照。
- 就诊时接受免疫抑制或RAAS抑制剂未增加死亡或急性肾损伤风险。
- 就诊时低血清白蛋白和较短肾小球疾病病程与急性肾损伤及肾脏替代治疗风险相关。
核心结论
- 合并COVID-19的肾小球肾炎患者死亡率和急性肾损伤风险高于无肾小球肾炎的普通人群对照,应密切监测,尤其就诊时血清白蛋白低者。
研究设计与样本
- IRoc-GN国际登记纳入北美和欧洲40例肾小球肾炎合并COVID-19患者,与80例按感染时间匹配的无肾小球肾炎COVID阳性对照比较。
主要发现
- 肾小球肾炎组死亡率15% vs 对照组5%,急性肾损伤39% vs 14%,肾脏替代治疗需求两组无统计学差异。
- 肾小球肾炎队列中就诊时接受免疫抑制或RAAS抑制剂未增加死亡或急性肾损伤风险。
- 肾小球肾炎队列中就诊时低血清白蛋白和较短肾小球疾病病程与急性肾损伤及肾脏替代治疗风险增加相关。
- 原发性肾小球肾炎与系统性自身免疫病(狼疮或血管炎)相关肾小球肾炎患者结局无差异。
临床怎么用
- 对合并COVID-19的肾小球肾炎患者应密切监测,尤其就诊时血清白蛋白低者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The effects of SARS-CoV-2 infection on individuals with immune-mediated glomerulonephritis, who are often undergoing immunosuppressive treatments, are unknown. Therefore, we created the International Registry of COVID infection in glomerulonephritis (IRoc-GN) and identified 40 patients with glomerulonephritis and COVID-19 followed in centers in North America and Europe. Detailed information on glomerulonephritis diagnosis, kidney parameters, and baseline immunosuppression prior to infection were recorded, as well as clinical presentation, laboratory values, treatment, complications, and outcomes of COVID-19. This cohort was compared to 80 COVID-positive control cases from the general population without glomerulonephritis matched for the time of infection. The majority (70%) of the patients with glomerulonephritis and all the controls were hospitalized. Patients with glomerulonephritis had significantly higher mortality (15% vs. 5%, respectively) and acute kidney injury (39% vs. 14%) than controls, while the need for kidney replacement therapy was not statistically different between the two groups. Receiving immunosuppression or renin-angiotensin-aldosterone system inhibitors at presentation did not increase the risk of death or acute kidney injury in the glomerulonephritis cohort. In the cohort with glomerulonephritis, lower serum albumin at presentation and shorter duration of glomerular disease were associated with greater risk of acute kidney injury and need for kidney replacement therapy. No differences in outcomes occurred between patients with primary glomerulonephritis versus glomerulonephritis associated with a systemic autoimmune disease (lupus or vasculitis). Thus, due to the higher mortality and risk of acute kidney injury than in the general population without glomerulonephritis, patients with glomerulonephritis and COVID-19 should be carefully monitored, especially when they present with low serum albumin levels.
引用
- Waldman M, Soler MJ, García-Carro C, et al. Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring. Kidney Int. 2020. PMID: 33181156. doi:10.1016/j.kint.2020.10.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。